LCM
PRTK

Laurion Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Laurion Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,100
Closed -$254K – 1932
2017
Q3 		$254K Buy
+10,100
New +$235K ﹤0.01% 1374

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Laurion Capital Management's PRTK Position: Q4 2017 in Review

Laurion Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017, closing a stake of 10,100 shares — an estimated $254K sold.

Laurion Capital Management first reported a position in PRTK in Q3 2017 and held it in 1 quarter. The position peaked at $254K in Q3 2017. 116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Laurion Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Laurion Capital Management sold 10,100 Paratek Pharmaceuticals, Inc. shares in Q4 2017, an estimated $254K.
  • Laurion Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • Laurion Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $254K in Q3 2017.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Laurion Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.